Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

Inclusion Criteria:

• Meets the American College of Rheumatology (ACR) 1987 revised criteria forclassification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening
• Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5tender joints (28-joint count) and at least 1 of the following at screening:C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h
• Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (upto 25 mg weekly) for at least 8 weeks prior to the baseline visit.

Exclusion Criteria:

• Subjects with other rheumatic diseases
• Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamouscell carcinoma or in situ cervical cancer)
• Any prior use of B cell-depleting therapy